ArticleCardiovascular diabetology2005
Metabolic effect of telmisartan and losartan in hypertensive patients with metabolic syndrome.
Article in Cardiovascular diabetology, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 189 citations in OpenAlex.
- Adjunctive telmisartan treatment on body metabolism in clozapine or olanzapine treated patients with schizophrenia: a randomized, double blind, placebo controlled trial.Psychopharmacology · 2019Trial
- Effects of telmisartan on glucose levels in people at high risk for cardiovascular disease but free from diabetes: the TRANSCEND study.Diabetes care · 2011Trial
- Telmisartan effects on insulin resistance in obese or overweight adults without diabetes or hypertension.Journal of clinical hypertension (Greenwich, Conn.) · 2010Trial
- [Antihypertensive and metabolic effects of telmisartan in patients with the metabolic syndrome in primary care--a field study].Wiener medizinische Wochenschrift (1946) · 2007Trial
- The effects of irbesartan and telmisartan on metabolic parameters and blood pressure in obese, insulin resistant, hypertensive patients.Journal of endocrinological investigation · 2006Trial
- Comparison of telmisartan with losartan, valsartan, and candesartan on the risk of new-onset diabetes mellitus.Journal of human hypertension · 2026Article
- Integrative Wound-Healing Effects ofInternational journal of molecular sciences · 2025Article
- Blood pressure-lowering effect of telmisartan compared to losartan among mild to moderate essential hypertensive adult subjects: A meta-analysis.Journal of family medicine and primary care · 2022Article
- Article
- The Antihypertensive Drug Telmisartan Protects Oligodendrocytes from Cholesterol Accumulation and Promotes Differentiation by a PPAR-γ-Mediated Mechanism.International journal of molecular sciences · 2021Article
- Association between dyslipidemia and antihypertensive and antidiabetic treatments in a China multicenter study.Journal of clinical hypertension (Greenwich, Conn.) · 2021Article
- Autophagy in metabolic syndrome: breaking the wheel by targeting the renin-angiotensin system.Cell death & disease · 2020Review
- Multi-Target Approaches in Metabolic Syndrome.Frontiers in pharmacology · 2020Review
- Anti-Diabetic Effect of Telmisartan Through its Partial PPARγ-Agonistic Activity.Diabetes, metabolic syndrome and obesity : targets and therapy · 2020Review
- Age Stratification in Genetic Variation of Lipoprotein Lipase in Metabolic Syndrome Javanese Ethnics of Indonesia.Open access Macedonian journal of medical sciences · 2019Article
- Effects of Telmisartan and Candesartan on the Metabolism of Lipids and Glucose in Kidney Transplant Patients: A Prospective, Randomized Crossover Study.Transplantation direct · 2019Article
- The role of the angiotensin II type I receptor blocker telmisartan in the treatment of non-alcoholic fatty liver disease: a brief review.Hypertension research : official journal of the Japanese Society of Hypertension · 2018Review
- Telmisartan is effective to ameliorate metabolic syndrome in rat model - a preclinical report.Diabetes, metabolic syndrome and obesity : targets and therapy · 2018Article
- Metabolic syndrome in hypertensive patients: An unholy alliance.World journal of cardiology · 2014Review
- Management of nonalcoholic fatty liver disease: an evidence-based clinical practice review.World journal of gastroenterology · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMetabolic syndrome is a cluster of common cardiovascular risk factors that includes hypertension and insulin resistance. Hypertension and diabetes mellitus are frequent comorbidities and, like metabolic syndrome, increase the risk of cardiovascular events. Telmisartan, an antihypertensive agent with evidence of partial peroxisome proliferator-activated receptor activity-gamma (PPARgamma) activity, may improve insulin sensitivity and lipid profile in patients with metabolic syndrome.
methodsIn a double-blind, parallel-group, randomized study, patients with World Health Organization criteria for metabolic syndrome received once-daily doses of telmisartan (80 mg, n = 20) or losartan (50 mg, n = 20) for 3 months. At baseline and end of treatment, fasting and postprandial plasma glucose, insulin sensitivity, glycosylated haemoglobin (HBA1c) and 24-hour mean systolic and diastolic blood pressures were determined.
resultsTelmisartan, but not losartan, significantly (p < 0.05) reduced free plasma glucose, free plasma insulin, homeostasis model assessment of insulin resistance and HbAic. Following treatment, plasma glucose and insulin were reduced during the oral glucose tolerance test by telmisartan, but not by losartan. Telmisartan also significantly reduced 24-hour mean systolic blood pressure (p < 0.05) and diastolic blood pressure (p < 0.05) compared with losartan.
conclusionAs well as providing superior 24-hour blood pressure control, telmisartan, unlike losartan, displayed insulin-sensitizing activity, which may be explained by its partial PPARgamma activity.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.